Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23174287 | 0.93 | L3MBTL1 (0.42) | GLAL3MBTL1ADORA1MEN1KMT2A | |
| SCHEMBL427684 | 0.83 | TDP1 (0.43) | L3MBTL1MEN1KMT2ATSHRATM | |
| SCHEMBL421300 | 0.80 | RORC (0.36) | NR1H2 | |
| SCHEMBL421514 | 0.80 | BCHE (0.36) | MEN1KMT2ANR1H2 | |
| SCHEMBL26694676 | 0.80 | CRHBP (0.40) | GLAL3MBTL1MEN1KMT2ACRHBP | |
| SCHEMBL424632 | 0.79 | BCHE (0.42) | MEN1KMT2ANR1H2 | |
| SCHEMBL26976053 | 0.78 | GLA (0.40) | GLAL3MBTL1KMT2ACRHBPCRHR2 | |
| SCHEMBL27087987 | 0.78 | MEN1 (0.38) | GLAL3MBTL1MEN1KMT2ACRHBP | |
| SCHEMBL30758195 | 0.78 | L3MBTL1 (0.40) | GLAL3MBTL1MEN1KMT2ACRHBP | |
| SCHEMBL3436434 | 0.76 | L3MBTL1 (0.43) | GLAL3MBTL1ADORA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017069601-A1 | SUBSTITUTED AMINOALKYLAZOLES AS MALARIAL ASPARTIC PROTEASE INHIBITORS | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2017-04-27 | — | — | WO | disclosed |
| EP-2239253-B1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-8415359-B2 | Phenylpyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20120022075-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-26 | — | — | US | disclosed |
| US-8017610-B2 | Phenylpyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110003787-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2239253-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003787-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | GCKR, GCK, SLC5A1 | GLA 2026/4885L3MBTL1 3855/4885ADORA1 915/4885 |
| US-20120022075-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | GCKR, GCK, SLC5A1 | GLA 2026/4885L3MBTL1 3855/4885ADORA1 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.